This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Johnson & Johnson has to face US antitrust claims over Stelara patent, judge rules

( August 16, 2024, 21:48 GMT | Official Statement) -- MLex Summary: CareFirst has standing to bring US antitrust claims over Johnson & Johnson’s patent covering a method for using the drug ustekinumab, according to a federal judge. “The alleged harm—the payment of supra-competitive prices for ustekinumab—is an injury that the antitrust laws were designed to prevent. And the amended complaint alleges that the payment of these prices was defendants’ ultimate goal when enforcing the ’307 patent to keep biosimilars off the market,” District Judge Jamar K. Walker said in an order denying dismissal. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections